Spun out of the Emory University School of Medicine, Otogenetics Corporation utilizes Next Generation Sequencing (NGS) technology to provide the most advanced genetic testing to the research institutions and clinical care providers. Otogenetics began offering NGS as a service to the commercial market in 2011 and launched its first clinical genetic test in the same year; â sequencing more than 100 genes associated with Syndromic and Non-Syndromic Hearing Loss. Otogenetics was the first laboratory in the USA to enroll in CAP NGS proficiency tests and received 100% accuracy each time. The company holds CLIA Certification and is licensed in Georgia, California, Florida, and New York* to provide clinical genetic testing. Otogenetics is CAP-accredited for NGS testing. Test offering now includes Hereditary Cancer Risk Assessment, Single Gene and Expanded Carrier Screening, NIPT, clinical exome, rare diseases, and other tests for personalized medicine or clinical trials
